Denisov A A, Nikolaeva O G
Vopr Virusol. 1995 Nov-Dec;40(6):277-9.
Study of the antiviral properties of recombinant human lymphotoxin obtained from Escherichia coli SG20050/pLT21 strain by microbiological synthesis showed this lymphotoxin to inhibit vesicular stomatitis virus on M-19 cells and exert a synergistic effect with recombinant human gamma-interferon. The drug exhibited no anti-HIV1 activity in experiments with MT4 cells pretreated with the virus or the drug itself; on the contrary, HIV1 reproduction in these cells was enhanced at low concentrations of the recombinant lymphotoxin.
通过微生物合成从大肠杆菌SG20050/pLT21菌株获得的重组人淋巴毒素的抗病毒特性研究表明,这种淋巴毒素可抑制水泡性口炎病毒在M-19细胞上的生长,并与重组人γ-干扰素发挥协同作用。在用病毒或该药物本身预处理的MT4细胞实验中,该药物未表现出抗HIV1活性;相反,在低浓度重组淋巴毒素作用下,这些细胞中的HIV1复制增强。